- Open Access
Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-κB dependent AP-1-mediated ICAM-1 expression in breast cancer cells
© Ahmed and Kundu; licensee BioMed Central Ltd. 2010
- Received: 7 December 2009
- Accepted: 7 May 2010
- Published: 7 May 2010
Breast cancer is one of the most frequently diagnosed cancer and accounts for over 400,000 deaths each year worldwide. It causes premature death in women, despite progress in early detection, treatment, and advances in understanding the molecular basis of the disease. Therefore, it is important to understand the in depth mechanism of tumor progression and develop new strategies for the treatment of breast cancer. Thus, this study is aimed at gaining an insight into the molecular mechanism by which osteopontin (OPN), a member of SIBLING (Small Integrin Binding LIgand N-linked Glycoprotein) family of protein regulates tumor progression through activation of various transcription factors and expression of their downstream effector gene(s) in breast cancer.
In this study, we report that purified native OPN induces ICAM-1 expression in breast cancer cells. The data revealed that OPN induces NF-κB activation and NF-κB dependent ICAM-1 expression. We also observed that OPN-induced NF-κB further controls AP-1 transactivation, suggesting that there is cross talk between NF-κB and AP-1 which is unidirectional towards AP-1 that in turn regulates ICAM-1 expression in these cells. We also delineated the role of mTOR and p70S6 kinase in OPN-induced ICAM-1 expression. The study suggests that inhibition of mTOR by rapamycin augments whereas overexpression of mTOR/p70S6 kinase inhibits OPN-induced ICAM-1 expression. Moreover, overexpression of mTOR inhibits OPN-induced NF-κB and AP-1-DNA binding and transcriptional activity. However, rapamycin further enhanced these OPN-induced effects. We also report that OPN induces p70S6 kinase phosphorylation at Thr-421/Ser-424, but not at Thr-389 or Ser-371 and mTOR phosphorylation at Ser-2448. Overexpression of mTOR has no effect in regulation of OPN-induced phosphorylation of p70S6 kinase at Thr-421/Ser-424. Inhibition of mTOR by rapamycin attenuates Ser-371 phosphorylation but does not have any effect on Thr-389 and Thr-421/Ser-424 phosphorylation of p70S6 kinase. However, OPN-induced phosphorylation of p70S6 kinase at Thr-421/Ser-424 is being controlled by MEK/ERK pathway.
These results suggest that blocking of OPN-induced ICAM-1 expression through mTOR/p70S6 kinase signaling pathway may be an important therapeutic strategy for the treatment of breast cancer.
- Electrophoretic Mobility Shift Assay
- p70S6 Kinase
- Luciferase Reporter Gene Assay
- Autoinhibitory Domain
Breast cancer is one of the major causes of death among all other cancers in women globally. It emerges through a multi-step process starting from hyperplasia to premalignant change, in situ carcinoma, and invasive breast cancer [1–3]. Osteopontin (OPN), a calcified ECM associated non collagenous, sialic acid rich, glycosylated phosphoprotein is secreted by majority of the normal and transformed cells . OPN isolated from different cellular sources, have molecular weight ranging from 44 kDa to 75 kDa due to differences in the post translational modifications . Many highly metastatic transformed cells synthesize high level of OPN than their normal counter parts. Recently it has been reported that OPN plays crucial role in cell migration and invasion by interacting with its receptor αvβ3 integrin by inducing the expression of urokinase plasminogen activator (uPA) and activation of matrix metalloproteinases (MMPs) in various cancer cells [5–9]. Increased level of OPN has been reported in number of human carcinomas, glioblastoma, and osteosarcoma and considered as a lead marker during breast cancer progression .
The mammalian target of rapamycin (mTOR), (also known as FRAP/RAFT/RAPT), a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) super family, is consisted of 2549 amino acids that are grouped into highly conserved domains [11, 12]. Previous reports have indicated that mTOR acts as a downstream molecule in the PI 3-kinase/Akt signaling pathway. It is an evolutionarily conserved 289-kDa serine-threonine kinase that regulates both cell growth and cell-cycle progression through its ability to integrate signals in response to nutrients and growth factors. mTOR is phosphorylated at Ser-2448 via the PI 3-kinase/Akt pathway and autophosphorylates at Ser-2481 [12–14]. mTOR initiates translation by activating the p70S6 kinase (S6K1) and by inhibiting the eIF4E inhibitor, 4E-BP1. By targeting mTOR, the immunosuppressant and anti-proliferative agent, rapamycin inhibits the signals required for cell-cycle progression, cell growth and proliferation in both normal and malignant cells. Interaction of FKBP12 (immunophilin FK506 binding protein 12 kDa)-rapamycin complex with mTOR inhibits its function and leads to dephosphorylation and inactivation of p70S6 kinase [14–16]. As a result, mTOR may act as an important target for regulation of cancer progression. Activation of p70S6 kinase involves a complex interplay among sequential phosphorylation events, which occur within distinct intramolecular regulatory domains. Phosphorylation of p70S6 kinase at Thr-421/Ser-424 exists in the autoinhibitory domain of carboxyl terminal, Thr-229 in activation loop, Thr-389 and Ser-371 in the linker domain, are very important for the activation of p70S6 kinase [17, 18]. The phosphorylation of p70S6 kinase at Thr-421/Ser-424 leads the phosphorylation of other regulatory site by release of pseudosubstrate suppression in the autoinhibitory domain leading to modulation of the kinase activity [19, 20]. However, the mechanism by which OPN regulates mTOR/p70S6 kinase activation in breast cancer cells is not well defined.
Nuclear factor κB (NF-κB) and activator protein-1 (AP-1) are key transcription factors that regulate the expression of many genes involved in inflammation, apoptosis, and oncogenesis . Many reports have demonstrated that these transcription factors are thought to be regulated by the same intracellular signal transduction pathway. The activity of NF-κB is regulated by its interaction with the family of NF-κB inhibitor known as IκB, which results in the formation of inactive NF-κB-IκB complex in the cytoplasm. In response to various stimuli, IκB kinase (IKK) phosphorylates IκB. The subsequent proteosome mediated degradation of IκB expose the nuclear localization signal of NF-κB, thus allowing its translocation to the nucleus where it activates the transcription of various target genes including ICAM-1 [21–23]. AP-1 is a group of basic leucine zipper (bZIP) transcription factor consisting of the Fos and Jun families. Extracellular stimuli and growth factor stimulate MAPK pathways which play important role in regulation of transcription factor AP-1, as its activation leads to the induction of c-Fos which associate to c-Jun to form an AP-1 heteromeric complex that can promote target gene expression [21, 24]. Our previous results showed that OPN induces cell motility, tumor growth and angiogenesis through NF-κB and AP-1 dependent activation and expressions of MMP-2, -9, uPA, Cox-2 and VEGF in various cancer cells [10, 25]. However, the signaling pathways by which OPN controls NF-κB and AP-1 activation and whether there is any cross talk between NF-κB and AP-1 in regulation of ICAM-1 expression is not well understood.
Cell adhesion is a crucial step for normal development and maintenance of tissues and organs. Cell-cell and cell-matrix interaction are mediated by dynamic interaction between various cell surface receptors which play important role in regulation of cancer progression. Based on the structure and functions, adhesion molecules are classified into four major categories: integrins, cadherins, selectins and immunoglobulins superfamilies. The various cell adhesion molecules also function as receptors for various ligands thereby control signal transduction pathways which ultimately regulate cell adhesion, proliferation, migration and differentiation [26, 27]. Intercellular adhesion molecule-1 (ICAM-1), also known as CD54 is a cell surface glycoprotein that belongs to the immunoglobin superfamily of adhesion molecules. It is expressed in breast cancer tissues. The process of tumor growth involves alterations in expression of adhesion molecules that may lead to destruction of tissue architecture leading to metastasis [28–30]. The mechanisms by which OPN regulates ICAM-1 expression through mTOR/p70S6 kinase and NF-κB/AP-1 pathways are not defined well.
In summary, we report that OPN regulates NF-κB mediated ICAM-1 expression in breast cancer cells. OPN-induced NF-κB controls unidirectional AP-1 activation, indicating a cross talk between NF-κB and AP-1 which in turn regulates ICAM-1 expression in these cells. We also investigated the role of mTOR and p70S6 kinase in OPN-induced ICAM-1 expression. Our results revealed that both mTOR and p70S6 kinase are involved in OPN-induced ICAM-1 expression. Overexpression of mTOR inhibits OPN-induced NF-κB and AP-1 DNA-binding and transcriptional activity. OPN selectively induces p70S6 kinase phosphorylation at Thr-421/Ser-424. However, overexpression of mTOR has no effect on regulation of OPN-induced Thr-421/Ser-424 phosphorylation. Inhibition of mTOR by rapamycin attenuates Ser-371 phosphorylation of p70S6 kinase. Moreover, OPN-induced phosphorylation of p70S6 kinase at Thr-421/Ser-424 is being controlled by MEK/ERK pathway. Thus, blocking OPN-induced ICAM-1 expression through mTOR and p70S6 kinase pathway may act as important target for the control of breast cancer.
Antibodies, Reagents, and Cell Lines
Rabbit polyclonal anti-ICAM-1, goat polyclonal anti-actin, mouse monoclonal anti-p70S6 kinase, mouse anti-p-ERK1/2 and rabbit anti-ERK2 antibodies were purchased from Santa Cruz Biotechnology. Rabbit anti-p-mTOR antibody was purchased from R&D Systems. Rabbit anti-mTOR, anti-p-p70S6K antibodies and rapamycin were purchased from Cell Signaling Technology. U0126 was obtained from Calbiochem. Anti-human αvβ3 integrin (MAB1976) blocking antibody was from Chemicon International. Lipofectamine 2000 was purchased from Invitrogen. AP-1 consensus oligonucleotide was purchased from Santa Cruz and NF-κB consensus oligonucleotide was purchased from Promega. The [γ-32p] ATP was purchased from Board of Radiation and Isotope Technology (Hyderabad, India). The human OPN was purified from milk as described previously  with minor modifications and used throughout this study. The low invasive (MCF-7) and highly invasive (MDA-MB-468) breast cancer cells were purchased from American Type Culture Collection (Manassas, VA). These cells were cultured in Dulbecco's modified Eagle's medium (DMEM) and leibovitz's L-15 supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 μg/ml streptomycin and 2 mM glutamine in a humidified atmosphere at 37°C.
Plasmids and DNA Transfection
The wild type and rapamycin resistant mTOR in pIRES-GFP expression vector were a generous gift from Dr. Rok Humar (University Hospital Basel, Switzerland). The wild type and rapamycin resistant HA-S6K1 (p70S6 kinase 1) in pRK7 expression vector were kind gift from Dr. John Blenis (Harvard Medical School, Boston). The super-repressor form of IκBα fused downstream to a FLAG epitope in an expression vector (pCMV4) was a gift from Dr. Dean Ballard (Vanderbilt School of Medicine, Nashville, TN). The wild type pCEFL-GFP-c-Fos was a kind gift from Dr. Omar A Coso (Laboratorio de Fisiologia y Biologia Molecular. Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. IFIBYNE-CONICET. ARGENTINA). The dominant negative c-Fos (also called as A-Fos) in pCMV500 expression vector was a kind gift from Dr. Nicole Darack (NCI, NIH). The wild type c-Jun in pRJB10B expression vector and dominant negative c-Jun in pELFIN expression vector were kind gifts from Dr. Jalam (Ochsner Clinic foundation, New Orleans, LA). The ICAM-1 Luc (containing 1393 bp of ICAM-1 promoter) construct was a kind gift from Dr. Arshad Rahman (University of Rochester School of Medicine, Rochester, New York). The MCF-7 cells were transiently transfected with cDNA using Lipofectamine 2000 according to manufacturer's instructions (Invitrogen). Transfected cells were used for ICAM-1 expression, NF-κB and AP-1-DNA binding, NF-κB, AP-1 and ICAM-1 luciferase assays and p70S6 kinase phosphorylation studies.
Western Blot Analysis
For ICAM-1 expression, MCF-7 and MDA-MB-468 cells were treated with OPN in a time and dose dependent manner. In separate experiments, MCF-7 cells were either transfected with various cDNA constructs or pretreated with 20 nM rapamycin for 1 h and then treated with 0.5 μM OPN and level of ICAM-1 was detected. For p70S6 kinase and mTOR phosphorylations, cells were treated with 0.5 μM OPN for 0-120 min. In other experiments, the cells were either transfected with mTOR constructs or pretreated with 20 nM rapamycin or 0-500 μM U0126 for 1 h and then treated with 0.5 μM OPN. The cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 5 mM dithiothreitol and 1 mM phenylmethylsulfonyl fluoride) and the protein concentrations in cleared supernatants were measured by using Bio-Rad protein assay. The supernatant (lysates) containing equal amount of total proteins (30 μg) were resolved by SDS-PAGE and electrotransferred from gel to nitrocellulose membranes. The membranes were incubated with anti-p-p70S6K, anti-p-mTOR, anti-p-ERK1/2 or anti-ICAM-1 antibodies and further incubated with horseradish peroxidase-conjugated IgG and detected by luminol reagent (Santa Cruz) according to the manufacturer's instruction. The same blots were re-probed with anti-actin or non phospho antibodies of respective molecules and detected.
Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA)
The NF-κB and AP-1 EMSA were performed as described earlier . Briefly, MCF-7 cells were treated with 0.5 μM OPN for 0-240 min at 37°C. In another experiments, cells were transfected with mTOR, treated with 20 nM rapamycin for 1 h and then with 0.5 μM OPN for 30 min. In separate experiments, cells were transfected with wt c-Jun, dominant negative c-Jun, c-Fos and A-Fos cDNAs and then treated with 0.5 μM OPN for 30 min. Cells were scraped, washed with phosphate-buffered saline (pH 7.4) and resuspended in hypotonic buffer (10 mM Hepes, (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.2 mM phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol), and allowed to swell on ice for 10 min. Cells were homogenized in a Dounce homogenizer. The nuclei were separated by spinning at 3300 ×g for 15 min at 4°C. The nuclear pellet was extracted in nuclear extraction buffer (20 mM Hepes, (pH 7.9), 0.4 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 2.5% glycerol, 0.5 mM phenylmethylsulfonyl fluoride and 0.5 mM DTT) for 30 min on ice, and centrifuged at 12,000 ×g for 15 min at 4°C. The supernatant was used as nuclear extract. The protein concentrations in the supernatant of nuclear extracts were measured by Bio-Rad protein assay. The nuclear extracts (10 μg) were incubated with 16 fmol of 32P labeled double stranded NF-κB (5'-AGT TGA GGG GAC TTT CCC AGG C-3') and AP-1 (5'-CGC TTG ATG ACT CAG CCG GAA-3') consensus oligonucleotide in binding buffer (250 mM Hepes, (pH 7.9), 5 mM EDTA, 5 mM DTT, 10% Nonidet P-40, 50% glycerol, and 500 mM NaCl) containing 1 μg of salmon sperm DNA. The DNA-protein complex was resolved on a native polyacrylamide gel, and analyzed by autoradiography.
Luciferase Reporter Gene Assay
The luciferase reporter gene assay was done as described . Briefly, MCF-7 cells were transfected with ICAM-1-Luc using Lipofectamine 2000 and treated with 20 nM rapamycin for 1 h and then with 0.5 μM OPN. In separate experiments, MCF-7 cells were transfected with NF-κB-Luc or AP-1-Luc and then either cotransfected with wt mTOR, rapamycin resistance mTOR or pretreated with 20 nM rapamycin for 1 h and then treated with OPN. In other experiments, cells were transfected with AP-1-Luc and cotransfected with IκBα super repressor or treated with 10 μg/ml anti-αvβ3 integrin blocking antibody for 3 h and then treated with OPN. In another experiments, cells were transfected with NF-κB-Luc and then either cotransfected with wt and dominant negative c-Jun, c-Fos or A-Fos and then treated with OPN. The transfection efficiency was normalized by cotransfecting the cells with pRL vector (Promega) containing a full length Renilla luciferase gene under the control of constitutively active promoter. The cells were harvested in passive lysis buffer and the luciferase activity was measured using the dual luciferase assay system (Promega) according to the manufacturer instruction. Changes in activity with respect to control were calculated.
OPN-induces ICAM-1 expression in breast cancer cells
Both mTOR and p70S6 kinase suppress OPN-induced NF-κB and AP-1 mediated ICAM-1 expression
To further study the role of mTOR/p70S6 kinase on ICAM-1 transcriptional activity in response to OPN; cells were transiently transfected with ICAM-1 luciferase reporter construct. Transfected cells were treated with rapamycin and then with OPN. The transfection efficiency was normalized by cotransfecting the cells with Renilla luciferase vector. Changes in luciferase activity with respect to control were calculated. The results indicated that OPN induces ICAM-1 transcriptional activity and rapamycin augments ICAM-1 transcription in response to OPN (Fig. 2C). To assess the role of NF-κB and AP-1 in OPN-induced ICAM-1 expression, MCF-7 cells were individually transfected with IκBα super repressor, wt and dominant negative c-Jun, and A-Fos and then treated with OPN. Cell lysates were analyzed by western blot using anti-ICAM-1 antibody. The results indicated that IκBα super repressor, dominant negative c-Jun and A-Fos suppressed whereas wt c-Jun enhanced OPN-induced ICAM-1 expression (Fig. 2D). Actin was used as loading control.
mTOR plays crucial role in OPN-induced NF-κB activation
OPN-induced AP-1 activation is downregulated by mTOR
OPN-induced cross talk between NF-κB and AP-1 is unidirectional towards AP-1
OPN induces phosphorylation of p70S6 kinase at Thr-421/Ser-424, but not at Thr-389 and Ser-371 and has no effect on mTOR phosphorylation at Ser-2448
OPN induces mTOR independent p70S6 kinase phosphorylation at Thr-421/Ser-424 through MEK/ERK pathway
Recent reports demonstrated that both stroma and tumor derived OPN regulate breast tumor progression. OPN is a matrix associated ECM protein and it's over expression confers malignant transformation in a variety of tumorigenic cell lines . OPN was found to be a metastasis associated protein in breast cancer. Rudland et al have reported that majority of the breast cancer patients showed significantly higher level of OPN expression than normal individuals . The level of serum OPN in patients with breast, lung and prostate cancers is higher as compared to controls. The concentration of OPN required in controlling various cellular signaling events leading to tumor progression is varied significantly. Earlier reports have shown that nanomolar concentrations of OPN regulate cell adhesion and migration through PI 3-kinase-dependent Akt phosphorylation pathway in prostate cancer cells. However, other studies have indicated that micromolar concentrations of OPN are required to regulate tumor growth through PI 3-kinase dependent uPA secretion and MMP activation in various cancer cells. Therefore, different concentrations of OPN might regulate these cellular functions depending on the degree of posttranslational modification, the sources from which it is obtained and the nature of cell lines used [10, 32]. Thus the role of OPN in various pathophysiological conditions, particularly in cancer, suggested that the variation in post-translational modification such as glycosylation, phosphorylation and sulfation generate the different functional forms that might alter its normal physiological functions.
Recently, Rosette et al. have reported that ICAM-1 is likely to play a major role in invasion of cancer cells leading to tumor growth and metastasis in breast cancer . However, the mechanism by which OPN regulates ICAM-1 expression in breast cancer cells is not well defined. Here, we provide the experimental evidence indicating that OPN induces ICAM-1 expression in breast cancer, MCF-7 cells. We also examined the role of mTOR and its downstream molecule, p70S6 kinase, in OPN-induced ICAM-1 expression and the data suggest that overexpression of both mTOR and p70S6 kinase inhibit whereas rapamycin augments OPN-induced ICAM-1 expression in MCF-7 cells. The data revealed that OPN induces ICAM-1 expression through NF-κB and AP-1 mediated pathway. Moreover, the results showed that rapamycin augments OPN-induced ICAM-1 promoter activity in these cells. Furthermore, OPN induces NF-κB activation and overexpression of mTOR suppresses NF-κB activation in these cells. Earlier reports have shown that inhibition of mTOR by rapamycin induced NF-κB activity in response to thrombin in endothelial cells .
Our data also revealed that overexpression of mTOR suppresses OPN-induced AP-1 activation and rapamycin enhances this OPN-induced effect. We also showed that OPN regulates cross-talk between NF-κB and AP-1 that leads to ICAM-1 expression in breast cancer cells. Here we provide the experimental evidence that OPN induces AP-1-DNA binding and overexpression of IκBα super repressor suppresses OPN-induced AP-1 transactivation. Moreover, the OPN-induced NF-κB activation is not being controlled by AP-1. These data suggested that OPN-induced cross talk between NF-κB and AP-1 is unidirectional towards AP-1. Previous report indicated that OPN regulates cell migration, adhesion, invasion, proliferation and intracellular signaling by interacting with its receptor αvβ3 integrin in various cell types ([10, 33] and ). Our data also showed that αvβ3 integrin blocking antibody suppresses OPN-induced AP-1 transcriptional activity in MCF-7 cells suggesting that OPN induces AP-1 transcriptional activation by interacting with its receptor αvβ3 intergrin. Thus, OPN upon binding with αvβ3 integrin induces AP-1 transcriptional activity through NF-κB mediated pathway indicating a cross talk between NF-κB and AP-1 which in turn regulates ICAM-1 expression. Recent reports indicated that several mTOR inhibitors are currently under evaluation in preclinical and clinical studies . In this study, we have shown that inhibition of mTOR and its downstream target p70S6 kinase by rapamycin potentiate OPN-induced ICAM-1 expression. The data are consistent with the earlier report that inhibition of mTOR enhances thrombin-induced ICAM-1 expression by accelerating and stabilizing NF-κB activation in endothelial cells . In our study, we have evaluated the role of OPN and rapamycin on phosphorylations of mTOR and p70S6 kinase and the data suggested that OPN does not phosphorylate mTOR at Ser-2448 and p70S6 kinase at Thr-389 and Ser-371, but at Thr-421/Ser-424 sites. However, rapamycin does not affect phosphorylation of mTOR at Ser-2448 and p70S6 kinase at Thr-389 and Thr-421/Ser-424 but it does inhibit basal level of phosphorylation of p70S6 kinase at Ser-371.
This study highlights the potential role of OPN to induce ICAM-1 expression through mTOR/p70S6 kinase pathway in breast cancer cells. The findings emphasize the importance of mTOR/p70S6 kinase pathway as a check point to regulate ICAM-1 expression in response to OPN. The data further revealed that OPN regulates cross talk between transcription factors NF-κB and AP-1 which is unidirectional towards AP-1 that in turn regulates ICAM-1 expression. Moreover, the results deciphered the role of OPN and rapamycin in regulating mTOR and p70S6 kinase phosphorylations and involvement of MEK/ERK pathway in this process. Breast cancer is one of the most debilitating diseases and earlier reports have shown that ICAM-1 plays important role in regulating invasion, tumor growth and metastasis in breast cancer. Therefore it is important to understand how OPN selectively regulate p70S6K/mTOR phosphorylation leading to NF-κB dependent AP-1 mediated ICAM-1 expression in breast cancer cells. Thus, the study suggests that blocking of OPN-induced ICAM-1 expression through mTOR/p70S6 kinase signaling may be an important therapeutic target for the management of breast cancer.
This work was supported in part by the Council of Scientific and Industrial Research (CSIR), New Delhi, Government of India (to M. A.).
- Kammerer S, Roth RB, Reneland R, Marnellos G, Hoyal CR, Markward NJ, Ebner F, Kiechle M, Schwarz-Boeger U, Griffiths LR, Ulbrich C, Chrobok K, Forster G, Praetorius GM, Meyer P, Rehbock J, Cantor CR, Nelson MR, Braun A: Large scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res. 2004, 64: 8906-10. 10.1158/0008-5472.CAN-04-1788View ArticlePubMedGoogle Scholar
- Beckmann MW, Niederacher D, Schnürch HG, Gusterson BA, Bender HG: Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med. 1997, 75: 429-39. 10.1007/s001090050128View ArticlePubMedGoogle Scholar
- Borg A, Ferno M, Peterson C: Predicting the future of breast cancer. Nat Med. 2003, 9: 16-8. 10.1038/nm0103-16View ArticlePubMedGoogle Scholar
- Sodek J, Ganss B, McKee MD: Osteopontin. Crit Rev Oral Biol Med. 2000, 11: 279-303. 10.1177/10454411000110030101View ArticlePubMedGoogle Scholar
- Das R, Mahabeleshwar GH, Kundu GC: Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem. 2003, 278: 28593-606. 10.1074/jbc.M303445200View ArticlePubMedGoogle Scholar
- Das R, Mahabeleshwar GH, Kundu GC: Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem. 2004, 279: 11051-64. 10.1074/jbc.M310256200View ArticlePubMedGoogle Scholar
- Philip S, Bulbule A, Kundu GC: Osteopontin stimulates tumor growth and activation of promatrixmetalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001, 276: 44926-35. 10.1074/jbc.M103334200View ArticlePubMedGoogle Scholar
- Philip S, Kundu GC: Osteopontin induces nuclear factor-kappa B-mediated promatrix metalloproteinase-2 activation through Ikappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem. 2003, 278: 14487-97. 10.1074/jbc.M207309200View ArticlePubMedGoogle Scholar
- Rangaswami H, Bulbule A, Kundu GC: Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem. 2004, 279: 38921-35. 10.1074/jbc.M404674200View ArticlePubMedGoogle Scholar
- Rangaswami H, Bulbule A, Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006, 16: 79-87. 10.1016/j.tcb.2005.12.005View ArticlePubMedGoogle Scholar
- Dancey JE: Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs. 2005, 14: 313-28. 10.1517/135437126.96.36.1993View ArticlePubMedGoogle Scholar
- Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 2004, 18: 1926-45. 10.1101/gad.1212704View ArticlePubMedGoogle Scholar
- Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH: RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologus to yeast TORs. Cell. 1994, 78: 35-43. 10.1016/0092-8674(94)90570-3View ArticlePubMedGoogle Scholar
- Peterson RT, Beal PA, Comb MJ, Schreiber SL: FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem. 2000, 275: 7416-23. 10.1074/jbc.275.10.7416View ArticlePubMedGoogle Scholar
- Navé BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR: Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999, 344: 427-31. 10.1042/0264-6021:3440427PubMed CentralView ArticlePubMedGoogle Scholar
- Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G: Mammalian TOR: a homeostatic ATP sensor. Science. 2001, 294: 1102-05. 10.1126/science.1063518View ArticlePubMedGoogle Scholar
- Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G: Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem. 2002, 277: 20104-12. 10.1074/jbc.M201745200View ArticlePubMedGoogle Scholar
- Weng QP, Andrabi K, Klippel A, Kozlowski MT, Williams LT, Avruch J: Phosphatidylinositol 3-kinase signals activation of p70 S6 kinase in situ through site-specific p70 phosphorylation. Proc Natl Acad Sci USA. 1995, 92: 5744-8. 10.1073/pnas.92.12.5744PubMed CentralView ArticlePubMedGoogle Scholar
- Ferrari S, Bannwarth W, Morley SJ, Totty NF, Thomas G: Activation of p70S6k is associated with phosphorylation of four clustered sites displaying Ser/Thr-Pro motifs. Proc Natl Acad Sci USA. 1992, 89: 7282-6. 10.1073/pnas.89.15.7282PubMed CentralView ArticlePubMedGoogle Scholar
- Han JW, Pearson RB, Dennis PB, Thomas G: Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. J Biol Chem. 1995, 270: 21396-403. 10.1074/jbc.270.41.23934View ArticlePubMedGoogle Scholar
- Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ: NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol. 2004, 24: 7806-19. 10.1128/MCB.24.17.7806-7819.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004, 3: 17-26. 10.1038/nrd1279View ArticlePubMedGoogle Scholar
- Minhajuddin M, Fazal F, Bijli KM, Amin MR, Rahman A: Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. J Immunol. 2005, 174: 5823-9.View ArticlePubMedGoogle Scholar
- Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M: Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol. 2002, 22: 6321-35. 10.1128/MCB.22.18.6321-6335.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 2006, 6: 819-30. 10.2174/156652406779010803View ArticlePubMedGoogle Scholar
- Moh MC, Zhang C, Luo C, Lee LH, Shen S: Structural and functional analyses of a novel ig-like cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells. J Biol Chem. 2005, 280: 27366-74. 10.1074/jbc.M500852200View ArticlePubMedGoogle Scholar
- Fiore E, Fusco C, Romero P, Stamenkovic I: Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene. 2002, 21: 5213-23. 10.1038/sj.onc.1205684View ArticlePubMedGoogle Scholar
- Zhang X, Wu D, Jiang X: Icam-1 and acute pancreatitis complicated by acute lung injury. J Pancreas. 2009, 10: 8-14.Google Scholar
- Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, Denissenko MF: Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005, 26: 943-50. 10.1093/carcin/bgi070View ArticlePubMedGoogle Scholar
- Hirohashi S, Kanai Y: Cell adhesion system and human cancer morphogenesis. Cancer Sci. 2003, 94: 575-81. 10.1111/j.1349-7006.2003.tb01485.xView ArticlePubMedGoogle Scholar
- Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002, 62: 3417-27.PubMedGoogle Scholar
- Behera R, Kumar V, Lohite K, Karnik S, Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis. 2010, 31: 192-200. 10.1093/carcin/bgp289View ArticlePubMedGoogle Scholar
- Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S, Zambonin-Zallone A, Ross FP, Teitelbaum SL, Cheresh D: Binding of osteopontin to the osteoclast integrin alpha v beta 3. Osteoporos Int. 1993, 3: 132-5. 10.1007/BF01621887View ArticlePubMedGoogle Scholar
- Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K, Mukherjee AB: Potential roles of osteopontin and alpha v beta 3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci USA. 1997, 94: 9308-13. 10.1073/pnas.94.17.9308PubMed CentralView ArticlePubMedGoogle Scholar
- Huang S, Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003, 3: 371-7. 10.1016/S1471-4892(03)00071-7View ArticlePubMedGoogle Scholar
- Pullen N, Thomas G: The modular phosphorylation and activation of p70s6k. FEBS Lett. 1997, 410: 78-82. 10.1016/S0014-5793(97)00323-2View ArticlePubMedGoogle Scholar
- Moser BA, Dennis PB, Pullen N, Pearson RB, Williamson NA, Wettenhall RE, Kozma SC, Thomas G: Dual requirement for a newly identified phosphorylation site in p70s6k. Mol Cell Biol. 1997, 17: 5648-55.PubMed CentralView ArticlePubMedGoogle Scholar
- Adwan H, Bauerle TJ, Berger MR: Down regulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. 2004, 11: 109-20. 10.1038/sj.cgt.7700659View ArticlePubMedGoogle Scholar
- Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR: Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol. 2004, 24: 1235-44.PubMedGoogle Scholar
- Chakraborty G, Jain S, Kundu GC: Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008, 68: 152-61. 10.1158/0008-5472.CAN-07-2126View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.